PFMP · Question #703
Assume you are a functional manager in your medical device company in research and development. Your scientists have determined a new product that will be a breakthrough for the company, and you…
The correct answer is D. Qualitative benefits. When proposing a new component to a Portfolio Review Board, component proposals typically include key descriptors defined by the portfolio governance framework. Qualitative benefits - non-financial, intangible value such as improved brand reputation, competitive positioning, or…
Question
Assume you are a functional manager in your medical device company in research and development. Your scientists have determined a new product that will be a breakthrough for the company, and you want to serve as the sponsor for this component and present it to your Portfolio Review Board. You will need resources from other parts of the company to commercialize it. As you prepare your proposal you are following the key descriptors set up by the portfolio staff and will include:
Options
- ARisk reduction
- BRegulatory and compliance issues
- CInternal and external dependencies
- DQualitative benefits
How the community answered
(37 responses)- A5% (2)
- B8% (3)
- C3% (1)
- D84% (31)
Explanation
When proposing a new component to a Portfolio Review Board, component proposals typically include key descriptors defined by the portfolio governance framework. Qualitative benefits - non-financial, intangible value such as improved brand reputation, competitive positioning, or scientific advancement - are a standard key descriptor in component proposals. While risk reduction (A), regulatory/compliance issues (B), and dependencies (C) are all valid considerations in portfolio management, the question asks specifically about what would be included as a key descriptor in the proposal itself, and qualitative benefits are a defining category used to characterize and justify a component's strategic value to the board.
Community Discussion
No community discussion yet for this question.